UroGen Pharma (URGN) Stock Price, Quote, News & History | Benzinga

SPY765.63−0.97%QQQ712.08−1.81%BTC/USD81,751.71−2.70%DIA526.27−0.27%GLD372.45−1.72%TLT81.20+1.20%

UroGen Pharma Ltd (URGN) Stock Price, Quote, News & History

URGNNASDAQ

Trade with Public

Trade with Public

$35.30

-0.18-0.51%

Last update: Oct 22, 9:48 AM

$35.48

N/A

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$35.23

Close

-

Volume / Avg.

9.80K / 886.29K

Day Range

$34.60 - $35.39

52 Wk Range

16.36 - 50.81

Market Cap

$1.72B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

33

Short Interest

16.27%

Days to Cover

9.91

Recent UroGen Pharma Ltd. News

3 Bullish Biotech Stocks With Explosive Growth Trends

Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp movement. This is

MarketBeat

Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday

Avi Kapoor

US Stocks Likely To Rebound After Sharp Decline Amid Israel-Iran Conflict: S&P 500 Historically Moves Higher After Wars, Says Expert

U.S. stock futures were trading higher on Monday following Friday's sharp declines. Futures of benchmark indices were higher in premarket.

Rishabh Mishra

Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week

UroGen Pharma shares are surging this week after the company gained FDA approval for ZUSDURI. The positive clinical trial results and an analyst upgrade fueled a significant stock price increase.

Henry Khederian

FDA Approves UroGen's Zusduri As First Drug For Recurrent Bladder Cancer

FDA approves UroGen's Zusduri for recurrent low-grade bladder cancer, offering a non-surgical alternative with sustained response outcomes.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-158.92M

Investing Cash Flow (TTM)

40.10M

Financing Cash Flow (TTM)

105.29M

Free Cash Flow (TTM)

-159.14M

Capital Expenditure (TTM)

-218.00K

Net Change in Cash (TTM)

-13.53M

Analyst Trends and Forecast

3

May

1

Jun

1

Jul

3

Aug

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.2

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.82B

PE Ratio (TTM)

-

PE Ratio (FWD)

31.15

PEG Ratio (TTM)

-

PS Ratio (TTM)

9.30

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-5.55%

Earnings Yield % (FWD)

3.21%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$2.71

Company Debt

Total Debt

$188.73M

LT Debt

$188.73M

LT Debt Issuance (TTM)

$65.35M

LT Debt Repayment (TTM)

-$2.56M

Total Cash

$79.13M

Debt to Equity

-

Issuance of Debt (TTM)

$62.78M

Repayment of Debt (TTM)

-$2.56M